Inhibitory Compounds Against Lung Cancer Found in Belamcanda chinensis

Recent scientific studies have discovered that Belamcanda chinensis (commonly known as xạ can) contains compounds capable of inhibiting the growth of non-small cell lung cancer (NSCLC).

Anticancer Effects of Belamcanda chinensis

A study published in the journal Heliyon in August 2024 showed that extracts from Belamcanda chinensis can inhibit the proliferation of NSCLC cells by interfering with key signaling pathways such as MAPK (Ras/Raf) and Akt. Specifically, the extract significantly reduced the expression of proteins Ras, Raf, Erk1/2, p-Erk1/2, Akt, and p-Akt, while promoting apoptosis (programmed cell death) and inhibiting cancer cell division.

In animal experiments using nude mice, the extract also suppressed tumor growth and the expression of proteins related to Ras and Akt. These results suggest potential clinical applications of Belamcanda chinensis in treating lung cancer, especially for patients with Ras or Raf gene mutations.

Key Active Compounds

Belamcanda chinensis contains various bioactive compounds, notably flavonoids such as tectorigenin and irigenin. These compounds have been shown to inhibit cancer cell growth by causing cell cycle arrest at the G1 phase and inducing expression of proteins like p21 (WAF1) and p27^kip1.

Caution and Usage

Although preliminary research shows promising anticancer potential of Belamcanda chinensis, its use should be supervised by medical professionals. Currently, there is insufficient clinical evidence to confirm its efficacy and safety for lung cancer treatment in humans. Therefore, it should not be used as a primary treatment without guidance from healthcare specialists.

For more information on how Belamcanda chinensis can support lung cancer treatment or combined therapeutic approaches, please consult medical experts or oncologists.